Home >> Signaling Pathways >> Tyrosine Kinase

Tyrosine Kinase

Products for  Tyrosine Kinase

  1. Cat.No. Product Name Information
  2. GC65966 BPI-9016M BPI-9016M is a potent, orally active, and selective dual c-Met and AXL tyrosine kinases inhibitor. BPI-9016M suppresses tumor cell growth, migration and invasion of lung adenocarcinoma. BPI-9016M  Chemical Structure
  3. GC41631 BPIQ-I BPIQ-I is a quinazoline that inhibits the tyrosine kinase activity of the epidermal growth factor receptor (IC50 = 0.025 nM). BPIQ-I  Chemical Structure
  4. GC19080 BPR1J-097 BPR1J-097 is a novel potent FLT3 inhibitor with an IC50 of 11 nM. BPR1J-097  Chemical Structure
  5. GC35544 BPR1J-097 Hydrochloride BPR1J-097 Hydrochloride is a novel and potent FLT3 inhibitor with an IC50 of 11?nM. BPR1J-097 Hydrochloride  Chemical Structure
  6. GC35545 BPR1K871 BPR1K871 is a potent and selective dual FLT3/AURKA inhibitor with IC50s of 19 nM and 22 nM for FLT3 and AURKA, respectively, acts as a preclinical development candidate for anti-cancer therapy. BPR1K871  Chemical Structure
  7. GC18718 bpV(pic) (potassium hydrate) bpV(pic) is a bisperoxovanadium (bpV) compound that inhibits several different protein tyrosine phosphatases (PTPs), with selectivity for PTEN (IC50 = 31 nM). bpV(pic) (potassium hydrate)  Chemical Structure
  8. GC42972 Brain-Derived Acidic Fibroblast Growth Factor (1-11) (bovine) (trifluoroacetate salt) Brain-derived acidic fibroblast growth factor (brain-derived aFGF) (1-11) is a peptide fragment of brain-derived aFGF. Brain-Derived Acidic Fibroblast Growth Factor (1-11) (bovine) (trifluoroacetate salt)  Chemical Structure
  9. GC19084 Brigatinib A highly potent and selective ALK inhibitor Brigatinib  Chemical Structure
  10. GC11692 Brivanib (BMS-540215) Brivanib (BMS-540215) (BMS-540215) is an ATP-competitive inhibitor against VEGFR2 with an IC50 of 25 nM, and has moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR-β. Brivanib (BMS-540215)  Chemical Structure
  11. GC14238 Brivanib Alaninate (BMS-582664) Brivanib alaninate (BMS-582664) is an ATP-competitive inhibitor against VEGFR2 with an IC50 of 25 nM; has moderate potency against VEGFR-1 and FGFR-1, but more than 240-fold against PDGFRβ. Brivanib Alaninate (BMS-582664)  Chemical Structure
  12. GC34509 BT-13 BT-13 is a potent and selective glial cell line-derived neurotrophic factor (GDNF) receptor RET agonist independently of GFLs, promoting neurite growth from sensory neurons in vitro and attenuates experimental neuropathy in the Rat. BT-13  Chemical Structure
  13. GC10944 Butein Protein kinase inhibitor Butein  Chemical Structure
  14. GC34529 c-Fms-IN-1 c-Fms-IN-1 is a FMS kinase inhibitor with an IC50 of 0.0008 μM. c-Fms-IN-1  Chemical Structure
  15. GC35663 c-Fms-IN-10 c-Fms-IN-10 is the derivative of thieno [3,2-d] pyrimidine, an kinase inhibitor of FMS (Colony stimulating factor-1 receptor, CSF-1R) with IC50 of 2 nM. c-Fms-IN-10  Chemical Structure
  16. GC66028 c-Fms-IN-13 c-Fms-IN-13 (compound 14) is a potent FMS kinase inhibitor with an IC50 value of 17 nM. c-Fms-IN-13 can be used as an anti-inflammatory agent. c-Fms-IN-13  Chemical Structure
  17. GC35664 c-Fms-IN-3 c-Fms-IN-3 is a novel c-Fms kinase inhibitor with a potential as anti-inflammatory agent and antirheumatic agent. c-Fms-IN-3  Chemical Structure
  18. GC35665 c-Fms-IN-8 c-Fms-IN-8 (compound 4a) is a colony stimulating factor-1 receptor (CSF-1R, c-FMS) Type II inhibitor, with an IC50 of 9.1 nM. c-Fms-IN-8  Chemical Structure
  19. GC35666 c-Fms-IN-9 c-Fms-IN-9 is a c-FMS inhibitor extracted from patent WO2014145023A1, Compound Example 7. c-Fms-IN-9 inhibits unphosphorylated c-FMS kinase (uFMS) and uKIT with IC50s of <0.01 μM and 0.1-1 μM, respectively. c-Fms-IN-9  Chemical Structure
  20. GC19106 c-Kit-IN-1 c-Kit-IN-1 is a potent inhibitor of c-Kit and c-Met with IC50s of <200 nM. c-Kit-IN-1  Chemical Structure
  21. GC35705 c-Kit-IN-2 c-Kit-IN-2 is a c-KIT inhibitor with an IC50 of 82 nM, shows superior antiproliferative activities against all the three GIST cell lines, GIST882, GIST430, and GIST48, with GI50s of 3, 1, and 2 nM, respectively. c-Kit-IN-2  Chemical Structure
  22. GC38595 c-Kit-IN-3 c-Kit-IN-3  Chemical Structure
  23. GC38756 c-Kit-IN-3 D-tartrate c-Kit-IN-3 D-tartrate  Chemical Structure
  24. GC38757 c-Kit-IN-3 hydrochloride c-Kit-IN-3 hydrochloride  Chemical Structure
  25. GC65948 c-Kit-IN-5-1 c-Kit-IN-5 is potent inhibitor of c-Kit, with IC50s of 22 nM and 16 nM in kinase assay and cell assay, respectively. c-Kit-IN-5 shows more than 200-fold selectivity for c-Kit over KDR, p38, Lck, and Src. c-Kit-IN-5 also exhibits desirable pharmacokinetic properties. c-Kit-IN-5-1  Chemical Structure
  26. GC35716 c-Met inhibitor 1 c-Met inhibitor 1 is an inhibitor of the c-Met receptor signaling pathway useful for the treatment of cancer including gastric, glioblastoma, and pancreatic cancer. c-Met inhibitor 1  Chemical Structure
  27. GC35717 c-met-IN-1 c-met-IN-1 (compound 16) is a potent and selective c-Met inhibitor, with IC50 of 1.1 nM, with antitumor activity.. c-met-IN-1  Chemical Structure
  28. GC33203 c-Met-IN-2 c-Met-IN-2 is a potent, selective and orally available c-Met inhibitor, with an IC50 of 0.6 nM, with antitumor activity. c-Met-IN-2  Chemical Structure
  29. GC32748 CA-4948 CA-4948 is a selective, potent and orally active interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, extracted from patent WO2015104688 (example 1). CA-4948  Chemical Structure
  30. GC15779 Cabozantinib (XL184, BMS-907351) Cabozantinib (XL184, BMS-907351) is a potent and orally active inhibitor of VEGFR2 and MET, with IC50 values of 0.035, and 1.3 nM, respectively. Cabozantinib (XL184, BMS-907351) displays strong inhibition of KIT, RET, AXL, TIE2, and FLT3 (IC50=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib (XL184, BMS-907351) shows antiangiogenic activity. Cabozantinib (XL184, BMS-907351) disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis. Cabozantinib (XL184, BMS-907351)  Chemical Structure
  31. GC12531 Cabozantinib malate (XL184) Cabozantinib malate (XL184) (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively. Cabozantinib malate (XL184)  Chemical Structure
  32. GC67948 Cabozantinib-d6 Cabozantinib-d6  Chemical Structure
  33. GC50024 Caffeic acid-pYEEIE Phosphopeptide ligand for src SH2 domain Caffeic acid-pYEEIE  Chemical Structure
  34. GC64564 Caffeic acid-pYEEIE TFA Caffeic acid-pYEEIE TFA, a non-phosphopeptide inhibitor, exhibits potent binding affinity for the GST-Lck-SH2 domain. Caffeic acid-pYEEIE TFA  Chemical Structure
  35. GC12910 Canertinib (CI-1033) Canertinib (CI-1033) (CI-1033;PD-183805) is a potent and irreversible EGFR inhibitor; inhibits cellular EGFR and ErbB2 autophosphorylation with IC50s of 7.4 and 9 nM. Canertinib (CI-1033)  Chemical Structure
  36. GC12087 Canertinib dihydrochloride A pan-ErbB tyrosine kinase inhibitor Canertinib dihydrochloride  Chemical Structure
  37. GC49433 Capsiate A capsaicin analog with diverse biological activities Capsiate  Chemical Structure
  38. GC43198 CAY10717 CAY10717 is a multi-targeted kinase inhibitor that exhibits greater than 40% inhibition of 34 of 104 kinases in an enzymatic assay at a concentration of 100 nM. CAY10717  Chemical Structure
  39. GC49094 CAY10781 An NRP-1/VEGF-A interaction inhibitor CAY10781  Chemical Structure
  40. GC40054 CCT241161 CCT241161 is a multi-kinase inhibitor that inhibits B-RAF, B-RAFV600E, C-RAF, Src, and LCK (IC50s = 252, 15, 6, 15, and 3 nM, respectively). CCT241161  Chemical Structure
  41. GC19092 CCT241736 CCT241736 is a potent and orally bioavailable dual FLT3 and Aurora kinase inhibitor, which inhibits Aurora kinases (Aurora-A Kd, 7.5 nM, IC50, 38 nM; Aurora-B Kd, 48 nM), FLT3 kinase (Kd, 6.2 nM), and FLT3 mutants including FLT3-ITD (Kd, 38 nM) and FLT3(D835Y) (Kd, 14 nM). CCT241736  Chemical Structure
  42. GC32623 CE-245677 CE-245677 is a potent reversible inhibitor of Tie2 and TrkA/B kinases with a cellular IC50s of 4.7 and 1 nM. CE-245677  Chemical Structure
  43. GC16421 Cediranib (AZD217) Cediranib (AZD217) (AZD2171) is a highly potent, orally available VEGFR tyrosine kinase inhibitor with IC50s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively. Cediranib (AZD217)  Chemical Structure
  44. GC33004 Cediranib maleate (AZD-2171 maleate) Cediranib maleate (AZD-2171 maleate) (AZD-2171 maleate) is a highly potent, orally available VEGFR inhibitor with IC50s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively. Cediranib maleate (AZD-2171 maleate)  Chemical Structure
  45. GC63458 Cedirogant Cedirogant (ABBV-157) is an orally active RORγt inverse agonist. Cedirogant  Chemical Structure
  46. GC35651 Cenisertib Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia. Cenisertib  Chemical Structure
  47. GC15145 CEP-28122 anaplastic lymphoma kinase (ALK) inhibitor CEP-28122  Chemical Structure
  48. GC35652 CEP-28122 mesylate salt CEP-28122 mesylate salt, a diaminopyrimidine derivative, is a potent, selective, and orally bioavailable ALK inhibitor, with an IC50 value of 1.9 nM for recombinant ALK kinase activity. CEP-28122 has antitumor activity in experimental models of ALK-positive human cancers. CEP-28122 mesylate salt has good pharmacodynamic and pharmacokinetic activity. CEP-28122 mesylate salt  Chemical Structure
  49. GC15273 CEP-37440 FAK/ALK inhibitor,potent and selective CEP-37440  Chemical Structure
  50. GC19102 CEP-40783 CEP-40783 is a potent, selective and orally available inhibitor of AXL and c-Met with IC50 values of 7 nM and 12 nM, respectively. CEP-40783  Chemical Structure
  51. GC11209 Cerdulatinib (PRT062070) Cerdulatinib (PRT062070) (PRT062070) is a selective Tyk2 inhibitor with an IC50 of 0.5 nM. Cerdulatinib (PRT062070) (PRT062070) also is a dual JAK and SYK inhibitor with IC50s of 12, 6, 8 and 32 for JAK1, 2, 3 and SYK, respectively. Cerdulatinib (PRT062070)  Chemical Structure
  52. GC45789 Ceritinib-d7 An internal standard for the quantification of ceritinib Ceritinib-d7  Chemical Structure
  53. GC34217 Cetuximab (C225) Cetuximab (C225) (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab (C225) has potent antitumor activity. Cetuximab (C225)  Chemical Structure
  54. GC63429 Cevidoplenib

    Cevidoplenib is an orally active spleen tyrosine kinase (Syk) inhibitor with potential anti-inflammatory and immunomodulatory effects[1].

    Cevidoplenib  Chemical Structure
  55. GC63455 Cevidoplenib dimesylate Cevidoplenib is an orally available inhibitor of spleen tyrosine kinase (Syk), with potential anti-inflammatory and immunomodulating activities. Cevidoplenib dimesylate  Chemical Structure
  56. GC34528 cFMS Receptor Inhibitor II cFMS Receptor Inhibitor II is a CSF1R kinase inhibitor. cFMS Receptor Inhibitor II  Chemical Structure
  57. GC65976 cFMS Receptor Inhibitor IV cFMS Receptor Inhibitor IV (Compound 42) is a potent cFMS inhibitor with an IC50 of 0.017 μM. cFMS Receptor Inhibitor IV  Chemical Structure
  58. GC31726 cFMS-IN-2 cFMS-IN-2 is a FMS kinase inhibitor with an IC50 of 0.024 μM. cFMS-IN-2  Chemical Structure
  59. GC33064 CG-806 (Luxeptinib) CG-806 (Luxeptinib) (CG-806) is an orally active, reversible, first-in-class, non-covalent and potent pan-FLT3/pan-BTK inhibitor. CG-806 (Luxeptinib) induces cell cycle arrest, apoptosis or autophagy in acute myeloid leukemia cells. CG-806 (Luxeptinib)  Chemical Structure
  60. GC15950 CGP 52411 EGFR inhibitor CGP 52411  Chemical Structure
  61. GC18438 CGP 77675 CGP 77675 is an inhibitor of Src family kinases (SFKs) that blocks the phosphorylation of peptide substrates and autophosphorylation of purified c-Src (IC50s = 5-20 and 40 nM, respectively). CGP 77675  Chemical Structure
  62. GC48992 CGP 77675 (hydrate) An inhibitor of Src family kinases CGP 77675 (hydrate)  Chemical Structure
  63. GC14650 CGP60474 A CDK inhibitor CGP60474  Chemical Structure
  64. GC10759 CH5183284 (Debio-1347) CH5183284 (Debio-1347) (Debio 1347) is an orally available and selective FGFR inhibitor with IC50s of 9.3, 7.6, and 22 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. CH5183284 (Debio-1347)  Chemical Structure
  65. GC16025 CH5424802 CH5424802 (CH5424802) is a potent, selective, and orally available ALK inhibitor with an IC50 of 1.9 nM and a Kd value of 2.4 nM (in an ATP-competitive manner), and also inhibits ALK F1174L and ALK R1275Q with IC50s of 1 nM and 3.5 nM, respectively. CH5424802 demonstrates effective central nervous system (CNS) penetration. CH5424802  Chemical Structure
  66. GC33112 CH7057288 CH7057288 is a potent and selective TRK inhibitor. CH7057288  Chemical Structure
  67. GC25219 CH7233163 CH7233163 is a non-covalent ATP competitive inhibitor of EGFR-tyrosine kinase with antitumor activities against tumor with EGFR-Del19/T790M/C797S. CH7233163  Chemical Structure
  68. GC62145 Chiauranib Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis. Chiauranib potently inhibits the angiogenesis-related kinases (VEGFR1, VEGFR2, VEGFR3, PDGFRα and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF-1R, with IC50 values ranging from 1-9 nM. Chiauranib has strongly anticancer effects. Chiauranib  Chemical Structure
  69. GC15739 CHIR-124 Chk1 inhibitor,novel and potent CHIR-124  Chemical Structure
  70. GC32979 Chloropyramine hydrochloride Chloropyramine hydrochloride is a histamine receptor H1 antagonist which can also inhibit the biochemical function of VEGFR-3 and FAK. Chloropyramine hydrochloride  Chemical Structure
  71. GC17294 CHMFL-ABL-053 BCR-ABL inhibitor CHMFL-ABL-053  Chemical Structure
  72. GC35682 CHMFL-ABL/KIT-155 CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155; compound 34) is a highly potent and orally active type II ABL/c-KIT dual kinase inhibitor (IC50s of 46 nM and 75 nM, respectively), and it also presents significant inhibitory activities to BLK (IC50=81 nM), CSF1R (IC50=227 nM), DDR1 (IC50=116 nM), DDR2 (IC50=325 nM), LCK (IC50=12 nM) and PDGFRβ (IC50=80 nM) kinases. CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155) arrests cell cycle progression and induces apoptosis. CHMFL-ABL/KIT-155  Chemical Structure
  73. GC33020 CHMFL-BMX-078 (CHMFL-BMX 078) CHMFL-BMX-078 (CHMFL-BMX 078) is a highly potent and selective type II irreversible BMX kinase inhibitor with an IC50 of 11 nM. CHMFL-BMX-078 (CHMFL-BMX 078)  Chemical Structure
  74. GC35684 CHMFL-EGFR-202 CHMFL-EGFR-202 is a potent, irreversible inhibitor of epidermal growth factor receptor (EGFR) mutant kinase, with IC50s of 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases, respectively. CHMFL-EGFR-202 exhibits ?10-fold selectivity for EGFR L858R/T790M against the EGFR wild-type in cells. CHMFL-EGFR-202 adopts a covalent “DFG-in-C-helix-out” inactive binding conformation with EGFR, with strong antiproliferative effects against EGFR mutant-driven nonsmall-cell lung cancer (NSCLC) cell lines. CHMFL-EGFR-202  Chemical Structure
  75. GC35685 CHMFL-KIT-033 CHMFL-KIT-033 is a potent and selective inhibitor of c-KIT T670I mutant for gastrointestinal stromal tumors (GISTs), with an IC50 of 0.045 μM. CHMFL-KIT-033  Chemical Structure
  76. GN10327 Chrysophanol Chrysophanol  Chemical Structure
  77. GC43268 Cinnamtannin B-1 Cinnamtannin B-1 is a proanthocyanidin polyphenol originally isolated from cinnamon bark that has antioxidant properties. Cinnamtannin B-1  Chemical Structure
  78. GC32713 Cintirorgon (LYC-55716) Cintirorgon (LYC-55716) (LYC-55716) is a first-in-class, selective and orally bioavailable RORγ agonist. Cintirorgon (LYC-55716) (LYC-55716) modulates gene expression of RORγ expressing T lymphocyte immune cells, resulting in enhanced effector function, as well as decreased immunosuppression, resulting in decreased tumor growth, and improved survival. Cintirorgon (LYC-55716)  Chemical Structure
  79. GC39485 CK2/ERK8-IN-1 A dual inhibitor of CK2 and ERK8 CK2/ERK8-IN-1  Chemical Structure
  80. GC17790 CL-387785 (EKI-785) CL-387785 (EKI-785)(EKI785; WAY-EKI 785) is an irreversible inhibitor of EGFR with IC50 of 370 pM. CL-387785 (EKI-785)  Chemical Structure
  81. GC11264 CNX-2006

    mutant-EGFR inhibitor, selective and irreversible

    CNX-2006  Chemical Structure
  82. GC14695 CO-1686 (AVL-301) A selective inhibitor of mutant EGFR CO-1686 (AVL-301)  Chemical Structure
  83. GC12837 Compound 56 A potent EGFR inhibitor Compound 56  Chemical Structure
  84. GC46123 Comprehensive Kinase Screening Library For screening of a variety of kinase inhibitors Comprehensive Kinase Screening Library  Chemical Structure
  85. GC35728 Conteltinib Conteltinib (CT-707) is a multi-kinase inhibitor targeting FAK, ALK, and Pyk2. Conteltinib exerts significant inhibitory effect on FAK with an IC50 of 1.6 nM. Conteltinib  Chemical Structure
  86. GC33352 CP-547632 A potent inhibitor of VEGFR2 and bFGF CP-547632  Chemical Structure
  87. GC38575 CP-547632 hydrochloride CP-547632 hydrochloride is an orally active, ATP-competitive and potent VEGFR-2 and FGF kinases inhibitor with IC50s of 11 nM and 9 nM, respectively. CP-547632 hydrochloride is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 hydrochloride has antitumor efficacy. CP-547632 hydrochloride  Chemical Structure
  88. GC60726 CP-547632 TFA CP-547632 TFA is an orally active, ATP-competitive and potent VEGFR-2 and FGF kinases inhibitor with IC50s of 11 nM and 9 nM, respectively. CP-547632 TFA is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 TFA has antitumor efficacy. CP-547632 TFA  Chemical Structure
  89. GC12980 CP-673451 PDGFRα/β inhibitor,potent and selective CP-673451  Chemical Structure
  90. GC13091 CP-724714 HER2 inhibitor,potent and selective CP-724714  Chemical Structure
  91. GC62274 CPL304110 CPL304110 is a potent, orally active and selective inhibitor of fibroblast growth factor receptors FGFR (1-3), with IC50 values of 0.75 nM, 0.5 nM, and 3.05 nM for FGFR (1-3), respectively. CPL304110  Chemical Structure
  92. GC14906 Crenolanib (CP-868596) Crenolanib (CP-868596) is a potent and selective inhibitor of wild-type and mutant isoforms of the class III receptor tyrosine kinases FLT3 and PDGFRα/β with Kds of 0.74 nM and 2.1 nM/3.2 nM, respectively. Crenolanib (CP-868596)  Chemical Structure
  93. GC12616 Crizotinib hydrochloride

    inhibitor of the c-Met kinase and the NPM-ALK

    Crizotinib hydrochloride  Chemical Structure
  94. GC38412 Crotonoside A guanosine analog with diverse biological activities Crotonoside  Chemical Structure
  95. GC25313 CS-2660 (JNJ-38158471) CS-2660 (JNJ-38158471) is a well tolerated, orally available, highly selective VEGFR-2 inhibitor with IC50 of 40 nM. CS-2660 (JNJ-38158471) also inhibits closely related tyrosine kinases such as RET (c-RET) and Kit (c-Kit) with IC50 of 180 nM and 500 nM,while it has no significant activity (>1 microM) against VEGFR-1 and VEGFR-3. CS-2660 (JNJ-38158471)  Chemical Structure
  96. GC33241 CSF1R-IN-1 CSF1R-IN-1 is a CSF1R inhibitor with an with an IC50 of 0.5 nM. CSF1R-IN-1  Chemical Structure
  97. GC64961 CSF1R-IN-2 CSF1R-IN-2 (compound 5) is an oral-active inhibitor of SRC, MET and c-FMS, with IC50 values of 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively. CSF1R-IN-2  Chemical Structure
  98. GC64805 CSF1R-IN-3 CSF1R-IN-3 (compound 21) is a potent and orally active CSF-1R inhibitor (IC50=2.1 nM). CSF1R-IN-3 is a potent antiproliferative activity against colorectal cancer cells. CSF1R-IN-3 inhibits the progression of colorectal cancer by suppressing the migration of macrophages, reprograming M2-like macrophages to the M1 phenotype, and enhancing the antitumor immunity. CSF1R-IN-3  Chemical Structure
  99. GC35753 CT-721 CT-721 is a potent and time-dependent Bcr-Abl kinase inhibitor with an IC50 of 21.3 nM for wild-type Bcr-Abl kinase, and possesses anti-chronic myeloid leukemia (CML) activities. CT-721  Chemical Structure
  100. GC67774 CT52923 CT52923  Chemical Structure
  101. GC50076 CTA 056 ITK inhibitor CTA 056  Chemical Structure

Items 201 to 300 of 1115 total

per page
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Set Descending Direction